Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Bionano Genomics, Inc. (BNGO) had Stock-Based Compensation of $3.61M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$7.37M |
|
$-8.50M |
|
$4.00M |
|
$3.37M |
|
$15.90M |
|
$-8.54M |
|
$0.05M |
|
$-8.49M |
|
$-8.49M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-8.50M |
|
$-8.54M |
|
$-6.35M |
|
5.34M |
|
5.34M |
|
$-1.59 |
|
$-1.59 |
|
| Balance Sheet Financials | |
$48.80M |
|
$16.17M |
|
$30.26M |
|
$79.06M |
|
$22.98M |
|
$3.50M |
|
$6.29M |
|
$29.26M |
|
$49.80M |
|
$44.11M |
|
$49.80M |
|
9.73M |
|
| Cash Flow Statement Financials | |
$-12.17M |
|
$-16.76M |
|
$22.44M |
|
$9.57M |
|
$3.06M |
|
$-6.51M |
|
|
Stock-Based Compensation |
$3.61M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.12 |
|
-- |
|
-- |
|
0.07 |
|
0.27 |
|
45.74% |
|
-115.90% |
|
-115.90% |
|
-- |
|
-115.23% |
|
-115.42% |
|
$-12.17M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
0.57 |
|
1.63 |
|
55.29 |
|
-17.07% |
|
-19.28% |
|
-10.75% |
|
-15.95% |
|
$5.12 |
|
$-2.28 |
|
$-2.28 |
|